Dasatinib-induced nephrotic-range proteinuria

American Journal of Kidney Diseases

Volumn 61, Issue 6, 2013, Pages 1026-1031

  Wallace, Eric ^a   Lyndon, William ^b   Chumley, Phillip ^a   Jaimes, Edgar A ^a,c   Fatima, Huma ^d  

^a University of Alabama at Birmingham   (United States)

^b Nephrology Associates   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Dasatinib; focal adhesion kinase; phosphopaxillin; proteinuria; vascular endothelial growth factor

Indexed keywords

CHOLESTEROL; CREATININE; DASATINIB; IMATINIB; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SERUM ALBUMIN; VASCULOTROPIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CHRONIC MYELOID LEUKEMIA; CREATININE BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LEUKEMIA REMISSION; NEPHROTIC SYNDROME;

FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; NEPHROTIC SYNDROME; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES;

EID: 84877924113     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.01.022     Document Type: Article

References (46)

1. B.J. Druker, F. Guilhot, S.G. O'Brien Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 23 2006 2408 2417
2. R.E. Gilbert, D.J. Kelly, T. McKay PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis Kidney Int 59 4 2001 1324 1332
3. M. Iyoda, K.L. Hudkins, S. Becker-Herman Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis J Am Soc Nephrol 20 1 2009 68 77
4. J. Savikko, J. Rintala, E. von Willebrand Early short-term platelet-derived growth factor inhibition prevents the development of chronic allograft nephropathy in experimental rat kidney transplantation Transplant Proc 38 10 2006 3231 3232
5. J. Savikko, J.M. Rintala, S.E. Rintala, P.K. Koskinen, E. von Willebrand Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy Nephrol Dial Transplant 26 9 2011 3026 3032
6. S. Wang, M.C. Wilkes, E.B. Leof, R. Hirschberg Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo FASEB J 19 1 2005 1 11
7. S. Wang, M.C. Wilkes, E.B. Leof, R. Hirschberg Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis Am J Physiol Renal Physiol 298 1 2010 F142 F149
8. C. Zoja, D. Corna, D. Rottoli, C. Zanchi, M. Abbate, G. Remuzzi Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease Kidney Int 70 1 2006 97 103
9. M. Lassila, K. Jandeleit-Dahm, K.K. Seah Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice J Am Soc Nephrol 16 2 2005 363 373
10. H. Ma, A. Togawa, K. Soda Inhibition of podocyte FAK protects against proteinuria and foot process effacement J Am Soc Nephrol 21 7 2010 1145 1156
11. A. Advani, K.J. Wiggins, A.J. Cox, Y. Zhang, R.E. Gilbert, D.J. Kelly Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy Nephrology 16 6 2011 573 581
12. M. Iyoda, T. Shibata, Y. Hirai, Y. Kuno, T. Akizawa Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease J Am Soc Nephrol 22 8 2011 1486 1496
13. V. Eremina, J.A. Jefferson, J. Kowalewska VEGF inhibition and renal thrombotic microangiopathy N Engl J Med 358 11 2008 1129 1136
14. D. Roncone, A. Satoskar, T. Nadasdy, J.P. Monk, B.H. Rovin Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma Nat Clin Pract Nephrol 3 5 2007 287 293
15. M.H. Kappers, F.M. Smedts, T. Horn The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system Hypertension 58 2 2011 295 302
16. G.D. Demetri, P. Lo Russo, I.R. MacPherson Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors Clin Cancer Res 15 19 2009 6232 6240
17. S. Ozkurt, G. Temiz, M.F. Acikalin, M. Soydan Acute renal failure under dasatinib therapy Renal Fail 32 1 2010 147 149
18. S.A. Holstein, J.B. Stokes, R.J. Hohl Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia Leuk Res 33 2 2009 344 347
19. R. Roskoski Jr Vascular endothelial growth factor (VEGF) signaling in tumor progression Crit Rev Oncol Hematol 62 3 2007 179 213
20. M. Simon, H.J. Grone, O. Johren Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney Am J Physiol 268 2, pt 2 1995 F240 F250
21. V. Eremina, M. Sood, J. Haigh Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases J Clin Invest 111 5 2003 707 716
22. R.J. Levine, S.E. Maynard, C. Qian Circulating angiogenic factors and the risk of preeclampsia N Engl J Med 350 7 2004 672 683
23. E. Bailey, M.J. Bottomley, S. Westwell Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation J Clin Pathol 52 10 1999 735 738
24. B. Hohenstein, M. Colin, C. Foellmer Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans Nephrol Dial Transplant 25 10 2010 3170 3180
25. H. Hurwitz Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer Clin Colorect Cancer 4 suppl 2 2004 S62 S68
26. K. Csaky, D.V. Do Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies Am J Ophthalmol 148 5 2009 647 656
27. T. Qaum, Q. Xu, A.M. Joussen VEGF-initiated blood-retinal barrier breakdown in early diabetes Invest Ophthalmol Vis Sci 42 10 2001 2408 2413
28. G. Pelle, N. Shweke, J.P. Duong Van Huyen Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors Am J Kidney Dis 57 5 2011 756 759
29. E.W. Ng, D.T. Shima, P. Calias, E.T. Cunningham Jr, D.R. Guyer, A.P. Adamis Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease Nat Rev Drug Discov 5 2 2006 123 132
30. R.S. Apte, M. Modi, H. Masonson, M. Patel, L. Whitfield, A.P. Adamis Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration Ophthalmology 114 9 2007 1702 1712
31. G. Bollee, N. Patey, G. Cazajous Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib Nephrol Dial Transplant 24 2 2009 682 685
32. T.V. Patel, J.A. Morgan, G.D. Demetri A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib J Natl Cancer Inst 100 4 2008 282 284
33. Y.S. Chen, C.L. Chen, J.S. Wang Nephrotic syndrome and acute renal failure apparently induced by sunitinib Case Rep Oncol 2 3 2009 172 176
34. D. Takahashi, K. Nagahama, Y. Tsuura, H. Tanaka, T. Tamura Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction Clin Exp Nephrol 16 2 2012 310 315
35. Y. Okuno, H. Kume, C. Hosoda, Y. Homma Development of nephrotic syndrome after administration of sorafenib in a case of metastatic renal cell carcinoma Case Rep Med 2011 2011 710216
36. I.J. Jonkers, M. van Buren Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma Clin Exp Nephrol 13 4 2009 397 401
37. E.S. Robinson, U.A. Matulonis, P. Ivy Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor Clin J Am Soc Nephrol 5 3 2010 477 483
38. B.D. Humphreys, M.B. Atkins Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res 15 19 2009 5947 5949
39. S.M. Thomas, J.S. Brugge Cellular functions regulated by Src family kinases Annu Rev Cell Dev Biol 13 1997 513 609
40. W. Liang, M. Kujawski, J. Wu Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment Clin Cancer Res 16 3 2010 924 935
41. C. Bertuccio, D. Veron, P.K. Aggarwal, L. Holzman, A. Tufro Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes J Biol Chem 286 46 2011 39933 39944
42. R. Verma, B. Wharram, I. Kovari Fyn binds to and phosphorylates the kidney slit diaphragm component nephrin J Biol Chem 278 23 2003 20716 20723
43. B. George, R. Verma, A.A. Soofi Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease J Clin Invest 122 2 2012 674 692
44. X. Zhu, S. Wu, W.L. Dahut, C.R. Parikh Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis Am J Kidney Dis 49 2 2007 186 193
45. S. Wu, C. Kim, L. Baer, X. Zhu Bevacizumab increases risk for severe proteinuria in cancer patients J Am Soc Nephrol 21 8 2010 1381 1389
46. E. Jefferson FDA approves additional medical indication for sprycel. FDA news release 2010 http://www.fda.gov Accessed September 12, 2012